First Author: P.Xanthopoulou GREECE
Co Author(s): J. Yfantopoulos A. Rouvas A. Chantzaras P. Theodosiadis 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate the efficacy of treatment with Ranibizumab (Lucentis® 0.5mg) in a sample of Greek patients with wet-AMD.
Attikon, University Hospital of Athens
In this observational, non-interventional, retrospective study, 194 cases with wet-AMD were enrolled from the Ophthalmology Clinic of the “Attikon” Hospital. Patients treated with Ranibizumab for at least one year in one eye under routine clinical practice, and had at least one follow-up visit, were considered eligible. Subjects participating in another study and/or were receiving pharmaceutical product containing VEGF inhibitors were excluded. Primary endpoint were the mean change in Best Corrected Visual Acuity (BCVA), and in Central retinal thickness (CRT), assessedby Optical Coherence Tomography.
The average BCVA score per eye at baseline was 0.284 in decimal points (Snellen equivalent≈ 20/84; ETDRS letters≈ 54), which improved at final visit (≈14 months after baseline) reaching 0.336 (Snellen equivalent≈ 20/60; ETDRS letters≈ 61), i.e. 18.3% or approximately 7 ETDRS letters improvement (p<0.001, r=0.317). CRT similarly improved, as it decreased by 28.4%, from 290.31to 207.77μm(p<0.001, r=0.683).An extra Ranibizumab injection per eye per year, increased the odds of anat least 0.1 increase in BCVA from baseline to last visit by 20.8% (95%CI 1.068-1.366), and an at least 0.2 increase by 15.7% (95%CI 1.013-1.322).
Ranibizumab (Lucentis® 0.5mg) provides significant benefit in patients with wet-AMD under routine clinical practice by improving BCVA and reducing CRT, benefit which may be more important in a more frequent dosing regimen.